Premium Essay

Upjohn Merger Case Analysis

In:

Submitted By amr1620
Words 1695
Pages 7
INTRODUCTION The 1990’s saw a highly fragmented pharmaceutical industry with many competitors. The top ten firms in pharmaceutical sales held 28% market share in mid-1995. The top 50 firms held just over 60 percent. Changes were occurring in the pharmaceutical industry in the 1990’s. With pharmaceutical benefit management (PBM) firms working to reduce costs, pharmaceutical firms held less power. PBMs sought to reduce the number of supplier firms by only purchasing from the largest firms and requiring doctors to prescribe drugs from approved lists called formularies. Many pharmaceutical firms saw mergers as a means of reducing costs and increasing market share. On August 20, 1995, two pharmaceutical companies by the names of Upjohn Company and Pharmacia AB announced that they were forming a “merger of equals.” Upjohn Company, incorporated in the U.S., and Pharmacia AB, incorporated in Sweden, would combine to form the ninth largest pharmaceutical company in the world. PHARMACEUTICAL INDUSTRY: PRE-MERGER The pharmaceutical industry at the time of the case was very attractive. The attractiveness of this industry can be determined using Porter’s Five Forces, a model for industry analysis. This model looks at barriers to entry, supplier power, threat of substitutes, and buyer power as they relate to industry rivalry. BARRIERS TO ENTRY The pharmaceutical industry has high barriers to entry. A company should expect to spend up to 15 years and up to $600 million to bring a new drug to market. On average, only one out of every 10,000 tested compounds becomes an approved drug. If a drug does make it to market, there is only a thirty-percent chance that revenues from the drug will exceed R&D costs. Based on these industry averages, a new firm hoping to enter the pharmaceutical industry should be prepared to dish out at least $600 million, without seeing an income

Similar Documents

Premium Essay

Upjhon Case

...The Upjohn Company: The Upjohn - Pharmacia Merger 3 Business Analysis and Valuation Applications harmacia & Upjohn will be a powerful new competitor in the global pharmaceutical industry. For both Pharmacia and Upjohn, this merger is a bold strategic move to build a highly competitive company as the worldwide pharmaceutical industry continues to consolidate. The new company will be positioned to attain its goals of revenue growth above the industry average and operating margins exceeding 25% by 1998. Jan Ekberg, President and CEO of Pharmacia Proposed Chairman of Pharmacia & Upjohn This is a merger that truly constitutes far more than the sum of the parts. The new company will be able to take full advantage of uniquely complementary geographic reach, product portfolio, pipeline and R&D strengths. As a result of the merger, Pharmacia & Upjohn will have extensive financial and operating resources, market scope and earnings potential. Consequently, we fully expect the new company to achieve additional growth in expected 1996 EPS as well as acceleration of future earnings growth. Above all, Pharmacia & Upjohn is expected to generate significantly enhanced value for shareholders. John L. Zabriskie, Ph.D., Chairman and CEO of Upjohn Proposed President and CEO of Pharmacia & Upjohn On August 20, 1995, The Upjohn Company and Pharmacia AB, two pharmaceutical companies incorporated in the U.S. and Sweden, respectively, announced that they were forming a “merger of equals.” With combined...

Words: 13956 - Pages: 56

Premium Essay

Professor

...February 28, 1997 The Upjohn Company: The Upjohn - Pharmacia Merger Pharmacia & Upjohn will be a powerful new competitor in the global pharmaceutical industry. For both Pharmacia and Upjohn, this merger is a bold strategic move to build a highly competitive company as the worldwide pharmaceutical industry continues to consolidate. The new company will be positioned to attain its goals of revenue growth above the industry average and operating margins exceeding 25% by 1998. Jan Ekberg, President and CEO of Pharmacia Proposed Chairman of Pharmacia & Upjohn. This is a merger that truly constitutes far more than the sum of the parts. The new company will be able to take full advantage of uniquely complementary geographic reach, product portfolio, pipeline and R&D strengths. As a result of the merger, Pharmacia & Upjohn will have extensive financial and operating resources, market scope and earnings potential. Consequently, we fully expect the new company to achieve additional growth in expected 1996 EPS as well as acceleration of future earnings growth. Above all, Pharmacia & Upjohn is expected to generate significantly enhanced value for shareholders. John L. Zabriskie, Ph.D. Chairman and CEO of Upjohn Proposed President and CEO of Pharmacia & Upjohn On August 20, 1995, The Upjohn Company and Pharmacia AB, two pharmaceutical companies incorporated in the U.S. and Sweden, respectively, announced that they were forming a “merger of equals.” With combined...

Words: 14768 - Pages: 60

Premium Essay

Fiduciary Duties

...FIDUCIARY DUTIES AND OTHER RESPONSIBILITIES OF CORPORATE DIRECTORS AND OFFICERS Morrison & Foerster LLP Christopher M. Forrester Celeste S. Ferber RR DONNELLEY EZ START XBRL We Tag. You Validate. We File. With the release of the proposed rule, the SEC will require the use of XBRL for financial reporting starting as early as 2009 for some companies. RR Donnelley is uniquely qualified to give you guidance on how your company can prepare for the SEC mandate. As the market leader in XBRL filings, we have been helping leading companies successfully tag and file XBRL financials since the inception of the SEC Voluntary Filing Program. RR Donnelley’s proven EZ Start XBRL full-service solution is designed to save you crucial time. With EZ Start, we do the initial tagging for you, reducing the time spent mapping and validating XBRL tags to under ten hours. Our goal is to transfer knowledge to your financial team to ensure a firm understanding of the taxonomies, mapping process and SEC requirements. To learn more, visit www.tryxbrl.com. FIDUCIARY DUTIES AND OTHER RESPONSIBILITIES OF CORPORATE DIRECTORS AND OFFICERS MORRISON & FOERSTER LLP Christopher M. Forrester Celeste S. Ferber RR Donnelley Global Capital Markets Copyright© 2008 Morrison & Foerster LLP (No claim to original U.S. Government works) All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic...

Words: 49138 - Pages: 197

Premium Essay

Critical Thinking

...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be an indepth discussion...

Words: 5468 - Pages: 22

Premium Essay

Xyz Pharama

...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be...

Words: 5468 - Pages: 22

Premium Essay

Xyz Pharma

...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be an indepth discussion...

Words: 5468 - Pages: 22

Premium Essay

A Study on Pharmaceutical Industry of Bangladesh from the Perspective of Corporate Finance ( Company Under Research: Beximco Pharmaceuticals Ltd & Square Pharmaceuticals Ltd)

...of Contents Chapter 01: Introduction 5 1.1 Introduction 5 1.2 Objective 5 1.3 Methodology 5 1.4 Limitation 5 Chapter 02: Brief Company Overview 6 2.1. Beximco Pharmaceuticals Ltd 6 2.2. Square Pharmaceuticals Ltd 7 Chapter 03: Capital Structure 8 3.1. What is a 'Capital Structure' 8 3.2. BREAKING DOWN 'Capital Structure' 8 3.3. Corporate Finance - Factors that Influence a Company's Capital-Structure Decision 8 3.4. Study on the Debt Equity Ratio Analysis 10 3.5. Observation: 11 Chapter 04: Dividend Policy & Dividend Payout 13 4.1. Dividend theories 13 4.2. Dividend Policy: 14 4.3. Dividend Policy of Beximco & Squar Pharma 15 4.4. Dividend Payout Ratio: 16 4.5. Analysis on Dividend Payout Ratio and its impact on average share price in the long run 19 Chapter 05: Effect of Dividend Declaration & Dividend Payment on Share price 20 5.1. Beximco Pharmaceuticals Ltd 20 5.2. Square Pharmaceuticals Ltd 22 Chapter 06: Merger 24 6.1. The Main Idea of Merger 24 6.2. Amalgamation of Beximco Infusion Ltd with Beximco Pharmaceuticals Ltd 26 Chapter 07: Conclusion 29 Bibliography 30 Chapter 01: Introduction 1.1 Introduction The pharmaceutical industry in Bangladesh is one of the most developed technology sectors within Bangladesh....

Words: 7998 - Pages: 32

Premium Essay

Merger & Acquisition

...Mergers, Acquisitions and Corporate Restructuring II MERGERS, ACQUISITIONS AND CORPORATE RESTRUCTURING Mergers, Acquisitions and Corporate Restructuring Edited by Chandrashekar Krishnamurti Vishwanath S.R. Copyright © Chandrashekar Krishnamurti and Vishwanath S.R., 2008 All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage or retrieval system, without permission in writing from the publisher. First published in 2008 by Response Books Business Books from SAGE B1/I-1 Mohan Cooperative Industrial Area Mathura Road, New Delhi 110 044, India SAGE Publications Inc 2455 Teller Road Thousand Oaks, California 91320, USA SAGE Publications Ltd 1 Oliver’s Yard, 55 City Road London EC1Y 1SP, United Kingdom SAGE Publications Asia-Pacific Pte Ltd 33 Pekin Street #02-01 Far East Square Singapore 048763 Published by Vivek Mehra for Response Books, typeset in 9.5/13 pt Berthold Baskerville by Star Compugraphics Private Limited, Delhi and printed at Chaman Enterprises, New Delhi. Library of Congress Cataloging-in-Publication Data Mergers, acquisitions and corporate restructuring/edited by Chandrashekar Krishnamurti, Vishwanath S.R. p. cm. Includes references and index. 1. Consolidation and merger of corporations. Corporate reorganizations. I. Vishwanath, S.R., 1971– II. Krishnamurti, Chandrashekar, 1956– HG4028.M4 .M44 658.1/6 22 2008...

Words: 62616 - Pages: 251

Premium Essay

International Business

...JOURNAL OF MANAGERIAL ISSUES Vol. XXII Number 4 Winter 2010: 456-475 Incumbents Adaptation to Competence-Destroying Change: Role of Prior Experience and Knowledge Sourcing Mujtaba Ahsan Assistant Professor of Management Pittsburg State University Assistant Professor of Management State University of New York at Oneonta Mine Ozer Assistant Professor of Management California State University, East Bay For the past several decades, the topic of new technological developments has been of interest to strategy scholars (Ansoff and Stewart, 1967; Cooper and Schendel, 1976; Rosenbloom and Cusamano, 1987; Rothaermel, 2001a, 2001b; Tushman and Anderson, 1986). Scholars have repeatedly focused on this topic as innovation and new product development are critical for a firm’s survival and growth (Penrose, 1995) and have stated that one of the core competencies needed to develop new technologies is the ability to assimilate and recombine knowledge in unique combinations (Rosenkopf and Nerkar, 2001). Simply put, successful innovation and new product development require the ability to create and use new knowledge to offer novel products or services to customers. Research indicates that firms who possess prior experience are in a better position to innovate (Carroll et al., 1996; Henderson and Cockburn, 1994; Klepper and Simons 2000; Nerkar and Roberts, 2004). Prior studies have also highlighted the importance of knowledge and experience in enabling firms to successfully adapt...

Words: 9421 - Pages: 38

Premium Essay

Masters in Business Administration

...C H A P T E R The External Environment 4 The Environmental Domain Task Environment • General Environment • International Context Environmental Uncertainty Simple-Complex Dimension • Stable-Unstable Dimension • Framework Adapting to Environmental Uncertainty Positions and Departments • Buffering and Boundary Spanning • Differentiation and Integration • Organic Versus Mechanistic Management Processes • Planning and Forecasting Resource Dependence Controlling Environmental Resources Establishing Interorganizational Linkages • Controlling the Environmental Domain • Organization-Environment Integrative Framework Chapter Four The External Environment 53 M any companies are surprised by changes in the external environment. Perhaps the greatest tumult for today’s organizations has been created by the rapid expansion of e-commerce. For example, Amazon.com was ringing up on-line book sales for more than a year before managers at Barnes & Noble even began thinking about a Web site. Barnes & Noble was highly successful with its book superstore concept, but its early efforts in e-commerce were marked by costly mistakes and missed opportunities. Even though the company burned through $100 million in an effort to “crush Amazon,” Barnesandnoble.com was still selling only 15 percent of books bought online compared to Amazon’s 75 percent.1 Firms in every industry, from auto manufacturing to telecommlunications, face similar uncertainty. Many factors in the external environment...

Words: 11140 - Pages: 45

Premium Essay

A Report on Working Capital Management

...Educarnival PediaAssignment, Internship Report, Term Paper • Home • Popular Post • Rules and Regulations • Educarnival Home Top of Form [pic][pic] Bottom of Form INVENTORY MANAGEMENT OF BEXIMCO PHARMACEUTICALS LIMITED August 14, 2012 | Author: shuktara | Posted in Technology and Operations Management • 0.00 / 5 5 • 1 / 5 • 2 / 5 • 3 / 5 • 4 / 5 • 5 / 5 0 votes, 0.00 avg. rating (0% score) |Table of Contents | |1 Chapter 1 | |1.1 Origin of the Report | |1.2 Background of the Report | |1.3 Scope of the Study | |1.4 Objectives of the Study | |1.5 Methodology of the Study | |1...

Words: 10543 - Pages: 43

Premium Essay

Performance Dynamics of an Industrial Enterprise in Bangladesh a Case Study of Beximco Pharma

...in late seventies they  have successfully maintained the quality of their products throughout, thereby earning the trust and faith of the society. Ingenious approaches on manufacturing, R&d and marketing remain the strategic objective during 2010 and beyond.  Origin of The Study: This report will be prepared as a part of the internship program which is an integral part of the BBA program under the Dept. of Accounting & Information Systems in the Faculty of Business Studies, University of Dhaka. The organization attachment was started on 18th July, 2010. This report on “Financial Performance Analysis of Beximco pharmaceuticals Ltd(BPL)” was assigned by academic supervisor Mohammad Moniruzzaman,ACA, Lecturer of Dept of Accounting & Information Systems, Faculty of Business Studies, University of Dhaka. Purpose of The Study: The purpose of the study is to make an analysis of Financial Performance of BPL in terms of Pharmaceuticals Industry. This study will attempt to understand the financial conditions of BPL on different segments such as liquidity, profitability & solvency. The purpose is also to make recommendations for improving the financial stability and soundness of different services provided to the shareholders of BPL. It is also the purpose...

Words: 11192 - Pages: 45

Premium Essay

Fairnees Cream for Men

...The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities December 2007 Michael Steiner, CFP®, CPA David H. Bugen, CFP®, MBA Brian Kazanchy, CFP®, CFA, MBA William T. Knox IV, CFP®, CFA, JD Margaret V. Prentice, MBA Lauren Goldfarb Mark P. Hurley Steven E. Cortez Christine L. Boudreaux Benjamin J. Robins Yvonne N. Kanner Shehzad Sippy Adam L. Bartkoski Ana M. Avila RegentAtlantic Capital, LLC Michael Steiner is a Wealth Manager and Principal with RegentAtlantic Capital, LLC, and head of the firm’s Pharmaceutical Executive Services Group (PESG). David H. Bugen is a Wealth Manager and Principal, and Brian Kazanchy is a Wealth Manager. William T. Knox IV is a Wealth Manager and Principal. Margaret V. Prentice is the Chief Marketing Officer and Principal, and Lauren Goldfarb is the Business Development Coordinator. Fiduciary Network, LLC Mark P. Hurley is President and CEO of Fiduciary Network, LLC. Steven E. Cortez is Executive Vice President. Christine L. Boudreaux is Director of Adviser Communications, and Benjamin J. Robins is General Counsel. Yvonne N. Kanner is Executive Vice President and COO, and Shehzad Sippy is a Research Analyst. Adam L. Bartkoski is Director of Adviser Operations and Development, and Ana M. Avila is an Intern. © Copyright Fiduciary Network, LLC, 2007 This material is for your private information, and we are not soliciting any action based upon it. Opinions expressed are our current views only, at the...

Words: 43374 - Pages: 174

Free Essay

Monsanto Report a Corporate Profile

...A CORPORATE PROFILE About Food & Water Watch Food & Water Watch works to ensure the food, water and fish we consume is safe, accessible and sustainable. So we can all enjoy and trust in what we eat and drink, we help people take charge of where their food comes from, keep clean, affordable, public tap water flowing freely to our homes, protect the environmental quality of oceans, force government to do its job protecting citizens, and educate about the importance of keeping shared resources under public control. Food & Water Watch 1616 P St. NW, Ste. 300 Washington, DC 20036 tel: (202) 683-2500 fax: (202) 683-2501 info@fwwatch.org California Office 25 Stillman St., Ste. 200 San Francisco, CA 94107 tel: (415) 293-9900 fax: (415) 293-8394 info-ca@fwwatch.org www.foodandwaterwatch.org Copyright © 2013 by Food & Water Watch. All rights reserved. This report can be viewed or downloaded at www.foodandwaterwatch.org. A CORPORATE PROFILE Executive Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Company History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Modern-Day Monsanto . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Monsanto’s Environmental Impact . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Market Share . . . . . . . . . . ....

Words: 7321 - Pages: 30

Premium Essay

Global and Transnational Business: Strategy and Management

...Global and Transnational Business: Strategy and Management Second Edition Global and Transnational Business: Strategy and Management Second Edition George Stonehouse Northumbria University David Campbell University of Newcastle-upon-Tyne Jim Hamill University of Strathclyde Tony Purdie Northumbria University Copyright # 2004 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (þ44) 1243 779777 Email (for orders and customer service enquiries): cs-books@wiley.co.uk Visit our Home Page on www.wileyeurope.com or www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to permreq@wiley.co.uk, or faxed to (þ44) 1243 770620. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services...

Words: 155276 - Pages: 622